 "CureVac CEO eyes coronavirus vaccine approval in third quarter of 2021")
BERLIN (Reuters) - German biotech company CureVac hopes to receive approval for its experimental COVID-19 vaccine in the third quarter of 2021, Chief Executive Franz-Werner Haas said on Thursday.
Haas told a news conference of foreign journalists that the company aimed to initiate rolling review of its vaccine in the first quarter of 2021.
The exact timing for final approval will depend on how many other shots are given the green light over the next few months, he added.
(Reporting by Caroline Copley and Ludwig Burger; Editing by Maria Sheahan)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app